Imaging study checks PSMA protein in progressive triple-negative breast cancer
Tests a PSMA imaging scan in adults with progressive triple-negative breast cancer.
Plain-language title generated from the registry record
Registry title: PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.
Key facts
- Where
- Brussels, BelgiumSee the site
- Phase
- Phase 2
Where in Belgium
- Institut Jules BordetBrussels, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jules Bordet Institute
- Trial code
- NCT06059469
- Record updated
- 18 July 2025
- Original description
This is a descriptive, prospective, single centre study. This study will assess PSMA expression via the uptake of radiolabelled PSMA-ligand using PET/CT imaging in mTNBC lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory mTNBC using the Lutetium-177 radiolabelled PSMA.Read full original descriptionShow less
PRISMA: A Single-centre, Prospective Phase II Imaging Study Using PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.
This is a descriptive, prospective, single centre study. This study will assess PSMA expression via the uptake of radiolabelled PSMA-ligand using PET/CT imaging in mTNBC lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory mTNBC using the Lutetium-177 radiolabelled PSMA.
Inclusion: Written informed consent in accordance with institutional guidelines and obtained prior to any study procedure; Women with ≥ 18 years-old; Eastern Cooperative Oncology Group Performance Status of 0 to 2; Confirmed diagnosis of progressive metastatic TNBC and presenting measurable disease on 18F-FDG PET/CT (performed within 2 weeks) or Brain MRI in case of progressive brain metastases (performed within 4 weeks) prior to PSMA PET/CT; Radiolabelled PSMA PET/CT has to be performed before the next treatment line initiation.
Exclusion: Other active neoplastic disease; Skin only metastatic disease; Patients with a significant medical, neuro-psychiatric, or surgical condition, which, in the investigator's opinion, may interfere with completion of the study; Pregnant or lactating patients; Treatment by another molecule that is the object of investigation within 30 days.